Study of BLU-808 in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-04-28
- Last Posted Date
- 2025-04-28
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 95
- Registration Number
- NCT06948032
- Locations
- 🇺🇸
Celerion, Inc., Lincoln, Nebraska, United States
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
Phase 2
Not yet recruiting
- Conditions
- Chronic Inducible UrticariaChronic Spontaneous Urticaria
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 105
- Registration Number
- NCT06931405
Study of BLU-808 in Allergic Rhinoconjunctivitis
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 54
- Registration Number
- NCT06922448
- Locations
- 🇨🇦
Red Maple Trials, Ottawa, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath